X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (68) 68
humans (67) 67
male (37) 37
middle aged (36) 36
female (32) 32
oncology (32) 32
hematology (31) 31
aged (28) 28
in situ hybridization, fluorescence (25) 25
karyotyping (25) 25
adult (22) 22
genetics & heredity (22) 22
chromosome aberrations (18) 18
lymphoma, b-cell, marginal zone - genetics (14) 14
translocation, genetic (14) 14
prognosis (13) 13
abridged index medicus (12) 12
beer (12) 12
biochemistry (12) 12
chemistry (12) 12
compositions or test papers therefor (12) 12
condition-responsive control in microbiological orenzymological processes (12) 12
enzymology (12) 12
measuring or testing processes involving enzymes, nucleicacids or microorganisms (12) 12
metallurgy (12) 12
microbiology (12) 12
mutation or genetic engineering (12) 12
organic chemistry (12) 12
processes of preparing such compositions (12) 12
spirits (12) 12
t (12) 12
vinegar (12) 12
wine (12) 12
aged, 80 and over (11) 11
in-situ hybridization (11) 11
compositions thereof (10) 10
culture media (10) 10
human necessities (10) 10
hygiene (10) 10
medical or veterinary science (10) 10
microorganisms or enzymes (10) 10
oncogene proteins, fusion - genetics (10) 10
preparations for medical, dental, or toilet purposes (10) 10
propagating, preserving or maintaining microorganisms (10) 10
agriculture (9) 9
animal husbandry (9) 9
care of birds, fishes, insects (9) 9
fishing (9) 9
forestry (9) 9
gene (9) 9
hunting (9) 9
lymphoma, b-cell - genetics (9) 9
new breeds of animals (9) 9
non-hodgkins-lymphoma (9) 9
peptides (9) 9
rearing or breeding animals, not otherwise provided for (9) 9
reverse transcriptase polymerase chain reaction (9) 9
trapping (9) 9
adolescent (8) 8
cytogenetics (8) 8
genetic aspects (8) 8
lymphoma, b-cell, marginal zone - pathology (8) 8
mucosa-associated lymphoid tissue lymphoma translocation 1 protein (8) 8
b-cell lymphoma (7) 7
chromosome deletion (7) 7
expression (7) 7
leukemia, myelogenous, chronic, bcr-abl positive - genetics (7) 7
lymphomas (7) 7
neoplasm proteins - genetics (7) 7
trisomy (7) 7
abnormalities (6) 6
animals (6) 6
cancer (6) 6
chromosomes, human, pair 18 (6) 6
cytogenetic analysis (6) 6
dna-binding proteins - genetics (6) 6
malignant-lymphoma (6) 6
survival (6) 6
translocation, genetic - genetics (6) 6
translocations (6) 6
bcl10 (5) 5
blotting, southern (5) 5
cell line, tumor (5) 5
chromosome banding (5) 5
chromosomes, human, pair 11 (5) 5
chromosomes, human, pair 14 - genetics (5) 5
chromosomes, human, pair 18 - genetics (5) 5
classification (5) 5
comparative genomic hybridization (5) 5
low-grade (5) 5
malt lymphoma (5) 5
myelodysplastic syndromes - genetics (5) 5
physics (5) 5
tissue (5) 5
treatment outcome (5) 5
villous lymphocytes (5) 5
acute myeloid-leukemia (4) 4
aneuploidy (4) 4
caspases (4) 4
caspases - genetics (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet, ISSN 0140-6736, 12/2017, Volume 390, Issue 10114, pp. 2790 - 2802
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2006, Volume 354, Issue 23, pp. 2419 - 2430
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 11/2009, Volume 106, Issue 47, pp. 19946 - 19951
A key element for the development of suitable anti-cancer drugs is the identification of cancer-specific enzymatic activities that can be therapeutically... 
T lymphocytes | Cytokines | B lymphocytes | B cell lymphoma | Cell lines | Antibodies | Signatures | Gene expression | Viability | Cells | DLBCL | NF-kB | CARMA1 | MULTIDISCIPLINARY SCIENCES | T-CELL | CHEMOTHERAPY | C-FLIP | MALIGNANCIES | INHIBITORS | DIFFERENTIATION | NF-KAPPA-B | EXPRESSION | LYMPHOCYTES | Cell Proliferation | Oligonucleotide Array Sequence Analysis | Humans | Gene Expression Regulation, Neoplastic | NF-kappa B - metabolism | Neoplasm Proteins - antagonists & inhibitors | Gene Expression Profiling | Neoplasm Proteins - metabolism | CARD Signaling Adaptor Proteins - genetics | Antineoplastic Agents - metabolism | CARD Signaling Adaptor Proteins - metabolism | Caspases - metabolism | Neoplasm Proteins - genetics | Lung Neoplasms - enzymology | Caspases - genetics | Lymphoma, Large B-Cell, Diffuse - enzymology | Guanylate Cyclase - metabolism | Caspase Inhibitors | Animals | NF-kappa B - genetics | B-Cell CLL-Lymphoma 10 Protein | Adaptor Proteins, Signal Transducing - genetics | Cell Line, Tumor | Guanylate Cyclase - genetics | Signal Transduction - physiology | Mice | Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein | Adaptor Proteins, Signal Transducing - metabolism | Physiological aspects | Lymphomas | Genetic aspects | B cells | Properties | Proteases | Proteins | Cell growth | Pharmacology | Enzyme kinetics | Index Medicus | Biological Sciences
Journal Article
Blood, ISSN 0006-4971, 09/2017, Volume 130, Issue 10, pp. 1274 - 1274
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2017, Volume 179, Issue 3, pp. 410 - 420
Male sex is associated with unfavourable pharmacokinetics and prognosis in elderly patients with diffuse large B‐cell lymphoma ( DLBCL ). We investigated... 
diffuse large B‐cell lymphoma | rituximab dose | sex | rituximab pharmacokinetics | diffuse large B-cell lymphoma | DSHNHL | RANDOMIZED CONTROLLED-TRIAL | PHASE-3 | CHEMOTHERAPY PLUS RITUXIMAB | TRANSPLANTATION | ACUTE HEMATOLOGICAL TOXICITY | MAINTENANCE | B-CELL LYMPHOMA | NON-HODGKINS-LYMPHOMA | CHOP | HEMATOLOGY | Doxorubicin - blood | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Antineoplastic Combined Chemotherapy Protocols - blood | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Rituximab - blood | Vincristine - blood | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Dose-Response Relationship, Drug | Aged, 80 and over | Vincristine - administration & dosage | Female | Doxorubicin - administration & dosage | Rituximab - adverse effects | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Lymphoma, Large B-Cell, Diffuse - pathology | Treatment Outcome | Prednisone - blood | Rituximab - administration & dosage | Cyclophosphamide - blood | Medication Adherence | Lymphoma, Large B-Cell, Diffuse - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sex Factors | Survival Analysis | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Aged patients | Care and treatment | Anthracyclines | Lymphomas | Corticosteroids | Analysis | Elderly people | Drugs | Toxicity | Sex | Males | Doxorubicin | Optimization | Risk factors | Rituximab | Pharmacology | Prednisone | Risk analysis | Survival | Patients | Vincristine | Lymphoma | Serum levels | Cyclophosphamide | Lymphocytes B | Medical prognosis | Females | Pharmacokinetics | Elderly | Geriatrics | B-cell lymphoma | Index Medicus
Journal Article
Tumori, 04/2019, p. 300891619839473
Progression of chronic myeloid leukemia (CML) is frequently accompanied by cytogenetic evolution, with an extra copy of the Philadelphia chromosome, trisomy 8... 
Journal Article
Journal Article
Blood, ISSN 0006-4971, 09/2010, Volume 116, Issue 9, pp. 1479 - 1488
Journal Article
BMC Cancer, ISSN 1471-2407, 06/2010, Volume 10, Issue 1, pp. 295 - 295
Background: Pancreatic cancer is still associated with devastating prognosis. Real progress in treatment options has still not been achieved. Therefore new... 
EXTRACELLULAR-MATRIX PROTEINS | NUDE-MICE | OVEREXPRESSION | CANCER CELLS | ONCOLOGY | DUCTAL ADENOCARCINOMA | SCID MICE | RESISTANCE | CARCINOEMBRYONIC ANTIGEN | EXPRESSION | TUMORS | Immunohistochemistry | Lung Neoplasms - drug therapy | Pore Forming Cytotoxic Proteins - genetics | Cell Proliferation | Pancreatic Neoplasms - metabolism | Oligonucleotide Array Sequence Analysis | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Lung Neoplasms - pathology | Male | DNA-Binding Proteins - deficiency | Dose-Response Relationship, Drug | Pancreatic Neoplasms - drug therapy | Adenocarcinoma - metabolism | Lung Neoplasms - secondary | Time Factors | Cell Shape | Karyotyping | Female | Adenocarcinoma - genetics | Antineoplastic Agents - pharmacology | Cell Culture Techniques | Lung Neoplasms - genetics | Cell Separation | Mice, Inbred C57BL | Pancreatic Neoplasms - pathology | Gene Expression Profiling - methods | In Situ Hybridization, Fluorescence | Pancreatic Neoplasms - genetics | Pore Forming Cytotoxic Proteins - deficiency | Tumor Burden | DNA-Binding Proteins - genetics | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Mice, Knockout | Xenograft Model Antitumor Assays | Animals | Cell Line, Tumor | Mice | Mutation | Gene amplification | Care and treatment | Prognosis | Lung cancer | Pancreatic cancer | Development and progression | Genetic aspects | Research | Risk factors | Index Medicus
Journal Article